Literature DB >> 16267026

Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.

Wenchang Guo1, Philip Reigan, David Siegel, Joseph Zirrolli, Daniel Gustafson, David Ross.   

Abstract

We have examined the role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the bioreductive metabolism of 17-allylamino-demethoxygeldanamycin (17-AAG). High-performance liquid chromatography (HPLC) analysis of the metabolism of 17-AAG by recombinant human NQO1 revealed the formation of a more polar metabolite 17-AAGH2. The formation of 17-AAGH2 was NQO1 dependent, and its formation could be inhibited by the addition of 5-methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione (ES936), a mechanism-based (suicide) inhibitor of NQO1. The reduction of 17-AAG to the corresponding hydroquinone 17-AAGH2 was confirmed by tandem liquid chromatography-mass spectrometry. 17-AAGH2 was relatively stable and only slowly underwent autooxidation back to 17-AAG over a period of hours. To examine the role of NQO1 in 17-AAG metabolism in cells, we used an isogenic pair of human breast cancer cell lines differing only in NQO1 levels. MDA468 cells lack NQO1 due to a genetic polymorphism, and MDA468/NQ16 cells are a stably transfected clone that express high levels of NQO1 protein. HPLC analysis of 17-AAG metabolism using cell sonicates and intact cells showed that 17-AAGH2 was formed by MDA468/NQ16 cells, and formation of 17-AAGH2 could be inhibited by ES936. No 17-AAGH2 was detected in sonicates or intact MDA468 cells. Following a 4-hour treatment with 17-AAG, the MDA468/NQ16 cells were 12-fold more sensitive to growth inhibition compared with MDA468 cells. More importantly, the increased sensitivity of MDA468/NQ16 cells to 17-AAG could be abolished if the cells were pretreated with ES936. Cellular markers of heat shock protein (Hsp) 90 inhibition, Hsp70 induction, and Raf-1 degradation were measured by immunoblot analysis. Marked Hsp70 induction and Raf-1 degradation was observed in MDA468/NQ16 cells but not in MDA468 cells. Similarly, downstream Raf-1 signaling molecules mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase and ERK also showed decreased levels of phosphorylation in MDA468/NQ16 cells but not in MDA468 cells. The ability of 17-AAG and 17-AAGH2 to inhibit purified yeast and human Hsp90 ATPase activity was examined. Maximal 17-AAG-induced ATPase inhibition was observed in the presence of NQO1 and could be abrogated by ES936, showing that 17-AAGH2 was a more potent Hsp90 inhibitor compared with 17-AAG. Molecular modeling studies also showed that due to increased hydrogen bonding between the hydroquinone and the Hsp90 protein, 17-AAGH2 was bound more tightly to the ATP-binding site in both yeast and human Hsp90 models. In conclusion, these studies have shown that reduction of 17-AAG by NQO1 generates 17-AAGH2, a relatively stable hydroquinone that exhibits superior Hsp90 inhibition.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16267026     DOI: 10.1158/0008-5472.CAN-05-2029

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  60 in total

1.  A mechanistic and structural analysis of the inhibition of the 90-kDa heat shock protein by the benzoquinone and hydroquinone ansamycins.

Authors:  Philip Reigan; David Siegel; Wenchang Guo; David Ross
Journal:  Mol Pharmacol       Date:  2011-02-01       Impact factor: 4.436

2.  Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.

Authors:  Takeshi Shimamura; Samanthi A Perera; Kevin P Foley; Jim Sang; Scott J Rodig; Takayo Inoue; Liang Chen; Danan Li; Julian Carretero; Yu-Chen Li; Papiya Sinha; Christopher D Carey; Christa L Borgman; John-Paul Jimenez; Matthew Meyerson; Weiwen Ying; James Barsoum; Kwok-Kin Wong; Geoffrey I Shapiro
Journal:  Clin Cancer Res       Date:  2012-07-17       Impact factor: 12.531

3.  Disruption of Heat Shock Protein 90 (Hsp90)-Protein Kinase Cδ (PKCδ) Interaction by (-)-Maackiain Suppresses Histamine H1 Receptor Gene Transcription in HeLa Cells.

Authors:  Yuki Nariai; Hiroyuki Mizuguchi; Takeyasu Ogasawara; Hiroaki Nagai; Yohei Sasaki; Yasunobu Okamoto; Yoshiyuki Yoshimura; Yoshiaki Kitamura; Hisao Nemoto; Noriaki Takeda; Hiroyuki Fukui
Journal:  J Biol Chem       Date:  2015-09-21       Impact factor: 5.157

4.  Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.

Authors:  Thomas D Zaikos; Mark M Painter; Nadia T Sebastian Kettinger; Valeri H Terry; Kathleen L Collins
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

5.  Geldanamycin-Derived HSP90 Inhibitors Are Synthetic Lethal with NRF2.

Authors:  Liam Baird; Takafumi Suzuki; Yushi Takahashi; Eiji Hishinuma; Daisuke Saigusa; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2020-10-26       Impact factor: 4.272

6.  Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives.

Authors:  Yayoi Fukuyo; Masahiro Inoue; Takuma Nakajima; Ryuji Higashikubo; Nobuko T Horikoshi; Clayton Hunt; Anny Usheva; Michael L Freeman; Nobuo Horikoshi
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

7.  Induction of premature senescence by hsp90 inhibition in small cell lung cancer.

Authors:  Ian J Restall; Ian A J Lorimer
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

8.  Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.

Authors:  J E Bohonowych; U Gopal; J S Isaacs
Journal:  J Oncol       Date:  2010-06-24       Impact factor: 4.375

9.  Collections of simultaneously altered genes as biomarkers of cancer cell drug response.

Authors:  David L Masica; Rachel Karchin
Journal:  Cancer Res       Date:  2013-01-21       Impact factor: 12.701

10.  Comparison and validation of genomic predictors for anticancer drug sensitivity.

Authors:  Simon Papillon-Cavanagh; Nicolas De Jay; Nehme Hachem; Catharina Olsen; Gianluca Bontempi; Hugo J W L Aerts; John Quackenbush; Benjamin Haibe-Kains
Journal:  J Am Med Inform Assoc       Date:  2013-01-26       Impact factor: 4.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.